Teladoc Health shares fell more than 28% after the company reported second-quarter 2026 consolidated revenue of $606.9 million, below the consensus range of $615 million to $628 million, and cut its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion. Levi & Korsinsky, LLP said it is investigating whether Teladoc made potentially materially false or misleading statements about its forward revenue outlook. The company had issued guidance on February 25, 2026 for $2.47 billion to $2.59 billion in revenue and projected a BetterHelp revenue decline of 7% to 0.5%, then narrowed those ranges on April 29, 2026 to approximately $2.48 billion to $2.57 billion and a BetterHelp decline of 6.5% to 1% for the full year. On the company's July 29, 2025 earnings call, Teladoc CEO, Charles Divita, said BetterHelp's outlook had assumed the business could scale insurance while stabilizing and growing segment revenue, but that the "decline in cash pay users … accelerated beyond the decline incorporated in our prior outlook" and insurance capacity "did not expand at the same pace as the increase in demand."